In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. - Wikidata - wikimedia - TriplyDB

In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner.

In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner.

http://www.wikidata.org/entity/Q36937137

about

Immunoregulatory functions of immune complexes in vaccine and therapy Therapeutic implications of autoantibodies in rheumatoid arthritis Targeting the Fc receptor in autoimmune disease Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms.Selective Deactivation of Serum IgG: A General Strategy for the Enhancement of Monoclonal Antibody Receptor Interactions Crystal structure of Streptococcus pyogenes EndoS, an immunomodulatory endoglycosidase specific for human IgG antibodies Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies Immunoglobulin M antiplatelet autoantibodies from mice immunized with rat platelets induce thrombocytopenia and platelet function impairment.Glycans are a novel biomarker of chronological and biological ages.Study of the IgG endoglycosidase EndoS in group A streptococcal phagocyte resistance and virulence.The IgG-specific endoglycosidase EndoS inhibits both cellular and complement-mediated autoimmune hemolysis.Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers.Fc-glycosylation of IgG1 is modulated by B-cell stimuli.EndoS reduces the pathogenicity of anti-mCOL7 IgG through reduced binding of immune complexes to neutrophils.IgG glycan hydrolysis attenuates ANCA-mediated glomerulonephritis.Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid.Microscale purification of antigen-specific antibodies.CP40 from Corynebacterium pseudotuberculosis is an endo-β-N-acetylglucosaminidase.Antiphagocytic function of an IgG glycosyl hydrolase from Streptococcus equi subsp. equi and its use as a vaccine component Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy.Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody.General mechanism for modulating immunoglobulin effector function.Dominant suppression of inflammation by glycan-hydrolyzed IgG Therapeutic potential of deglycosylated antibodies.Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita EndoS2 is a unique and conserved enzyme of serotype M49 group A Streptococcus that hydrolyses N-linked glycans on IgG and α1-acid glycoprotein.Liquid-liquid diffusion crystallization improves the X-ray diffraction of EndoS, an endo-β-N-acetylglucosaminidase from Streptococcus pyogenes with activity on human IgG Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside.Complex genetic regulation of protein glycosylation.Structure and function of immunoglobulins Chemoattractant-mediated leukocyte trafficking enables HIV dissemination from the genital mucosa.Evolutionary-developmental perspectives on immune system interactions among the pregnant woman, placenta, and fetus, and responses to sexually transmitted infectious agents.Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies.Targeting B cells and autoantibodies in the therapy of autoimmune diseases.Type I and type II Fc receptors regulate innate and adaptive immunity.Mechanisms of tissue damage in arthritis.Fcγ receptor pathways during active and passive immunization.Discovering potential drug-targets for personalized treatment of autoimmune disorders - what we learn from epidermolysis bullosa acquisita.In vivo enzymatic modulation of IgG antibodies prevents immune complex-dependent skin injury.

P2860

Q26738396-C897DD3D-698F-472D-8D63-46E573FDF4A1 Q26744033-DFB8C580-AD14-4AC0-A464-50A2A705D3B7 Q27002843-30957441-2074-4A9C-A23C-88E6C7DBDA7B Q27314948-D83C13D0-003A-4F50-81A1-484C1882655D Q27678384-E5DB4D50-3038-4354-9FF8-3F2F5751BC83 Q27683509-7481F791-7B99-4621-9D09-52356BBA5D44 Q28069362-9C7E5687-887D-4F6F-AD30-6E2AFBC8AE4D Q33393120-456C65E6-6995-433F-A5ED-2E00AD02A84E Q33725107-24BB91BA-B4C9-46C9-B727-91CFF5842A35 Q33914405-5BB5507E-4B8F-4E3A-943C-6B6726FB6D8D Q33931736-4A46890E-7092-427D-9D70-D54ED7F894F2 Q34574913-B2A6E8AB-B1D0-4FF9-83E1-741CE0B856E7 Q34994340-916B4DDE-A7C7-4617-8434-B1E7B4BC0EDF Q35087854-1442F3AD-F4A9-4ECD-85CF-64B5BEEEEF32 Q35153201-DEA9CE0F-42D8-4352-A88D-0D42B3A82BB3 Q35873009-CD4C7B9F-9D1D-43E3-9CF9-2A7152CE96E8 Q36157114-BEFB16B1-8D10-471E-84E1-E9E8524A3420 Q36184582-39D72BCA-05D5-4320-869A-F7B48FCC9FAC Q36211146-A04BBBF2-F9CC-4AAA-B222-3DB6E2443E17 Q36401731-A4157D19-EA30-4154-9FDB-C36F146463F7 Q36596808-05589E5F-2871-4784-B457-03A823F23FB0 Q36932153-DEB6332F-F013-45D0-882B-17BECDF5CBCB Q36950370-A0F0D891-8A8B-4D50-AA4F-CA7FF0C67044 Q36950457-855714F9-DD33-4AEB-9595-C786C6EDFD37 Q37055162-29E1A7D4-EC1A-49DF-A432-C1517EFB041A Q37186877-319E3A67-A6A4-422F-B979-23599284A6DD Q37374699-A94E9335-5D1F-40C6-80E2-8735A7299848 Q37578120-6A4F65C4-A860-4604-8081-910620A21516 Q37679726-589BC660-952F-4329-9AF9-DF5FC43BE6B0 Q37696721-7D3AEAF8-DDD9-47F2-A66F-BA296E1D7E14 Q37730789-A64DCB10-52F4-4F23-B57C-4DF162B055BA Q37913474-ABE7ED9B-CA42-4B27-8D94-D75CF1E47921 Q37998314-8188F40D-A0B2-472D-A76D-4F1C43BAB2BC Q38117686-C3C64A44-495D-4C51-A559-08B2C0B4F233 Q38207937-09DF9F9F-6383-4106-975B-371ECBC72FD1 Q38232105-A84C651F-E1E9-4E6A-A9F5-FAB7DDCED5D9 Q38248430-AB4C29E2-C7B9-42CF-9FE4-64475F84718F Q38615357-5D78CCEF-FD79-492A-A7F5-F02E54CD74EA Q38720806-DF5ACE0B-93C8-40B2-AFB4-F418AC237F8C Q38832411-048C922F-6477-401F-BBC2-297C60A8184F

P2860

In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner.

http://www.wikidata.org/entity/Q36937137

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

In vivo enzymatic modulation o ...... IgG subclass-dependent manner.

@en

type

label

In vivo enzymatic modulation o ...... IgG subclass-dependent manner.

@en

prefLabel

In vivo enzymatic modulation o ...... IgG subclass-dependent manner.

@en

P1433

Q36937137-C5A57A8B-77C1-48E3-ABBB-B7959F47BF78

P1476

Q36937137-83674A2F-C281-4D67-A8BE-084A6A2EA20F

P2093

Q36937137-07D5D9EA-174C-4D4E-99A6-65E52916B6D9

Q36937137-599F326E-EC35-4316-8B87-74C8CCB8944A

Q36937137-B3B8D4BD-5E86-4809-8497-2DF24A651DE0

Q36937137-B8F2ADD5-BA48-4201-B3CA-CBC9260AA987

Q36937137-BF17FA7F-D064-461A-8E4C-E2FC02B6AC74

P2860

Q36937137-0292CAE1-4DA5-4361-A184-A0DA1A42367F

Q36937137-0B2D327C-D8E9-41B0-BC88-787481093A5F

Q36937137-0B50F39B-F336-4105-B8FF-0DDF78308C50

Q36937137-148FE6CA-46E2-467E-A54A-BEEEE1AB3469

Q36937137-15623DC0-BD90-48C4-B66D-FF5C3BAA1AD1

Q36937137-16525743-F009-4750-B490-8C5032247D87

Q36937137-1759B934-333E-41D6-BAF8-6B624DBA970B

Q36937137-24BE0369-B9EF-40A7-9321-DF7D49AF1230

Q36937137-2698EB95-8583-4B28-BCE5-C55D86D49D51

Q36937137-3048D75C-BD90-4264-9E3D-B9769BDA0A29

P304

Q36937137-FE050D16-90CB-4915-A87C-96CE159F8821

P31

Q36937137-C0408594-0826-4F10-9091-ECEAE7830A02

P356

Q36937137-23863389-8B69-4F04-BDFF-69490996BF93

P407

Q36937137-6DE8E4DC-981B-48B7-9D7F-1319BFF2AF11

P433

Q36937137-668BF599-A5AE-464C-A68E-54634DF278AD

P478

Q36937137-3513547B-D35C-445C-91ED-DB3DD28ED363

P577

Q36937137-8485665D-1863-4C61-996A-DAF659EAC80D

P5875

Q36937137-9FCE7522-1F58-4B61-A806-839FD04E8994

P698

Q36937137-3DC61275-5635-45AB-B803-A23B97FA5014

P921

Q36937137-6F715C28-00C7-4F75-B1EE-684285B33369

P932

Q36937137-7D586D68-AEFB-40AC-AE7D-7B01F64CA82D

P356

PNAS.0808248105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

In vivo enzymatic modulation o ...... IgG subclass-dependent manner.

@en

P2093

Diana Dudziak

http://www.w3.org/2001/XMLSchema#string

Falk Nimmerjahn

http://www.w3.org/2001/XMLSchema#string

Heike Albert

http://www.w3.org/2001/XMLSchema#string

Jeffrey V Ravetch

http://www.w3.org/2001/XMLSchema#string

Mattias Collin

http://www.w3.org/2001/XMLSchema#string

P2860

Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity

EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG

Human IgG/Fc gamma R interactions are modulated by streptococcal IgG glycan hydrolysis

FcgammaRIV: a novel FcR with distinct IgG subclass specificity

Fcgamma receptors as regulators of immune responses

IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation.

Subclass restriction and polyclonality of the systemic lupus erythematosus marker antibody anti-Sm.

IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G.

Genetic dissection of the effects of stimulatory and inhibitory IgG Fc receptors on murine lupus.

IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions.

P304

15005-15009

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0808248105

http://www.w3.org/2001/XMLSchema#string

P407

P433

39

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23278712

http://www.w3.org/2001/XMLSchema#string

P698

18815375

http://www.w3.org/2001/XMLSchema#string

P921

P932

2567483

http://www.w3.org/2001/XMLSchema#string